Thursday, November 12, 2026

AI Economics

2 articles

Goldman Forecasts 7-Point Big Tech ROE Drop as AI Capex Fails to Deliver Returns

Goldman Forecasts 7-Point Big Tech ROE Drop as AI Capex Fails to Deliver Returns

Goldman Sachs has forecast a 7 percentage point decline in Big Tech return on equity, citing AI capital expenditure that has not yet translated to measurable business returns. The bank published an AI spending and profitability report alongside the bearish ROE forecast, signaling institutional concern about the current AI investment cycle. Markets are now pricing in near-term derating of AI infrastructure stocks as margin compression outpaces revenue uplift.

LM Salvado•
Nobel Economist Says AI Will Deliver a 'Small' Productivity Boost—Not the Revolution Markets Are Pricing

Nobel Economist Says AI Will Deliver a 'Small' Productivity Boost—Not the Revolution Markets Are Pricing

Nobel laureate Daron Acemoglu argues AI will give only a modest productivity boost and won't eliminate human work, colliding with equity valuations built on transformative automation assumptions. The disconnect sharpens as CPI runs at 3.8%, gasoline costs rise $857 per household, and consumer sentiment deteriorates among the income cohorts most likely to buy AI tools.

LM Salvado•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com